BiomX (PHGE) Debt Ratio (2018 - 2023)

BiomX (PHGE) posted Debt Ratio of 0.45 for Q4 2023, up 16.32% sequentially from 0.38 in Q3 2023, and up 36.83% YoY from 0.33 in Q4 2022.

BiomX (PHGE) Debt Ratio (2018 - 2023) Analysis & Trends

BiomX has reported Debt Ratio for 6 years, with the latest figure at 0.45 in Q4 2023.

Quarterly Debt Ratio rose 36.83% year-over-year to 0.45 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was 0.45 (up 36.83% YoY) and the FY2023 annual result came in at 0.45, up 36.83% from the prior year.
Debt Ratio climbed to 0.45 in Q4 2023 per PHGE's latest filing, from 0.38 in the prior quarter.
Over five years, Debt Ratio peaked at 0.45 in Q4 2023 and troughed at 0.01 in Q2 2019.
A 5-year average of 0.17 and a median of 0.18 in 2021 frame the typical range for Debt Ratio.
The sharpest annual moves came in 2021 and 2023: Debt Ratio soared 596.55% in 2021, then retreated 20.6% in 2023.
Over 5 years, Debt Ratio stood at 0.01 in 2019, then soared by 526.96% to 0.08 in 2020, then soared by 133.07% to 0.2 in 2021, then soared by 67.29% to 0.33 in 2022, then soared by 36.83% to 0.45 in 2023.
According to Business Quant data, Debt Ratio over the past three periods registered 0.45, 0.38, and 0.21 for Q4 2023, Q3 2023, and Q2 2023 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	0.05
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	0.05
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	0.12
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	0.03
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	0.26
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	0.47
10	BiomX	351,774.34	-816,225.66	-	-

Download Data